Royalty Pharma plc - Class A Ordinary Shares (RPRX)
RPRX moved a median of +0.14% 30 minutes after news, and +0.23% by the close. How RPRX actually reacts to news — the realized, point-in-time move the market made, measured across 382 labeled events over the last three years with zero look-ahead.
RPRX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.09% | 56% | 382 |
| 30-min | +0.14% | 55% | 382 |
| 60-min | +0.04% | 51% | 382 |
| to close | +0.23% | 61% | 375 |
| Middle 50% of RPRX reactions | -0.53% to +0.80% |
|---|---|
| Median reaction (30-min) | +0.14% |
| Measured reactions | 382 |
Half of all Royalty Pharma plc - Class A Ordinary Shares news events land between -0.53% and +0.80% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How RPRX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 17 | -0.02% | 47% | +0.15% |
| Analyst downgrades | 17 | -0.06% | 35% | +0.03% |
| Rating reiterations | 33 | 0.00% | 49% | 0.00% |
| Price-target raises | 10 | +0.01% | 50% | +0.02% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how RPRX ranks against every other measured name →
That’s how RPRX usually reacts — get an email when it moves on news →Email me when RPRX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to RPRX's baseline. Nothing else.
Recent RPRX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Royalty Pharma declares fourth quarter 2026 dividend | Press release | GlobeNewswire | -0.28% | +1.79% | |
| Royalty Pharma to announce third quarter 2026 financial results on November 4, 2026 | Press release | GlobeNewswire | +0.25% | +1.61% | |
| Royalty Pharma announces $7.5 million gift to Blood Cancer United to expand Therapy Acceleration Program | Press release | GlobeNewswire | +0.09% | -0.90% | |
| Royalty Pharma to present at upcoming investor conferences | Press release | GlobeNewswire | +0.13% | -2.73% | |
| Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen | Press release | GlobeNewswire | +0.79% | +2.35% | |
| Form 13F-NT Royalty Pharma plc For: Jun 30 | SEC filing · Form 13F-NT | SEC EDGAR | +0.15% | +0.39% | |
| Royalty Pharma and Zealand Pharma enter into rusfertide funding agreement for $100 million | Press release | GlobeNewswire | -0.02% | -1.58% | |
| Form 10-Q Royalty Pharma plc For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.10% | -2.99% | |
| Form 8-K Royalty Pharma plc For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | -1.10% | -2.99% | |
| Royalty Pharma reports second quarter 2026 results | Press release | GlobeNewswire | -1.10% | -2.99% | |
| Royalty Pharma appoints Greg Raskin as Senior Vice President, Head of Academic Initiatives | Press release | GlobeNewswire | -0.60% | -1.87% | |
| Royalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from Neurimmune | Press release | GlobeNewswire | +0.05% | +0.46% | |
| Royalty Pharma declares third quarter 2026 dividend | Press release | GlobeNewswire | +0.58% | -1.79% | |
| Royalty Pharma to announce second quarter 2026 financial results on August 5, 2026 | Press release | GlobeNewswire | +0.32% | +3.28% | |
| Form 8-K Royalty Pharma plc For: Jun 04 | SEC filing · Form 8-K | SEC EDGAR | +0.34% | +1.09% | |
| Royalty Pharma to present at the Goldman Sachs 47th Annual Global Healthcare Conference | Press release | GlobeNewswire | +0.34% | +1.09% | |
| Form 8-K Royalty Pharma plc For: May 22 | SEC filing · Form 8-K | SEC EDGAR | +0.75% | +2.35% | |
| Form 13F-NT Royalty Pharma plc For: Mar 31 | SEC filing · Form 13F-NT | SEC EDGAR | +0.10% | +0.63% | |
| Royalty Pharma to present at upcoming investor conferences | Press release | GlobeNewswire | +0.22% | +0.02% | |
| Form 10-Q Royalty Pharma plc For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -1.45% | -1.51% | |
| Form 8-K Royalty Pharma plc For: May 06 | SEC filing · Form 8-K | SEC EDGAR | -1.45% | -1.51% | |
| Royalty Pharma reports first quarter 2026 results | Press release | GlobeNewswire | -1.45% | -1.51% | |
| Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific Innovation | Press release | GlobeNewswire | +0.08% | +0.23% | |
| Royalty Pharma Declares Second Quarter 2026 Dividend | Press release | GlobeNewswire | +0.58% | +2.88% | |
| Royalty Pharma to Announce First Quarter 2026 Financial Results on May 6, 2026 | Press release | GlobeNewswire | +0.73% | -0.04% | |
| Form 8-K Royalty Pharma plc For: Apr 13 | SEC filing · Form 8-K | SEC EDGAR | +0.21% | -0.06% | |
| Form ARS Royalty Pharma plc For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.15% | +1.17% | |
| Form DEF 14A Royalty Pharma plc For: Jun 04 | SEC filing · Form DEF | SEC EDGAR | +0.15% | +1.17% | |
| Form DEFA14A Royalty Pharma plc | SEC filing · Form DEFA14A | SEC EDGAR | +0.15% | +1.17% | |
| Form 13F-NT Royalty Pharma plc For: Dec 31 | SEC filing · Form 13F-NT | SEC EDGAR | +0.03% | +0.66% | |
| Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases | Press release | GlobeNewswire | +0.07% | -0.21% | |
| Royalty Pharma Appoints Lucas Glass as Head of Artificial Intelligence | Press release | GlobeNewswire | -0.62% | -0.65% | |
| Royalty Pharma Announces Expansion of Leadership Team | Press release | GlobeNewswire | +0.13% | -0.43% | |
| Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing | Press release | GlobeNewswire | +1.35% | +3.49% | |
| Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform | Press release | GlobeNewswire | +1.35% | +3.49% | |
| Royalty Pharma to Present at TD Cowen’s 46th Annual Health Care Conference | Press release | GlobeNewswire | +0.45% | +1.70% | |
| Form 10-K Royalty Pharma plc For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.65% | +3.05% | |
| Form 8-K Royalty Pharma plc For: Feb 11 | SEC filing · Form 8-K | SEC EDGAR | +0.65% | +3.05% | |
| Royalty Pharma Reports Q4 and Full Year 2025 Results | Press release | GlobeNewswire | +0.65% | +3.05% | |
| Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026 | Press release | GlobeNewswire | +0.28% | +1.30% | |
| Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | -0.92% | -0.42% | |
| Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo | Press release | GlobeNewswire | -0.92% | -0.42% | |
| Royalty Pharma Announces Dividend Increase | Press release | GlobeNewswire | +0.37% | -0.94% | |
| Royalty Pharma Acquires Remaining Royalty Interest in Roche’s Evrysdi for $240 Million and Potential Milestones | Press release | GlobeNewswire | +0.38% | -0.10% | |
| Form 8-K Royalty Pharma plc For: Dec 19 | SEC filing · Form 8-K | SEC EDGAR | +0.09% | +0.59% | |
| Form 8-K Royalty Pharma plc For: Dec 20 | SEC filing · Form 8-K | SEC EDGAR | +0.49% | +1.42% | |
| Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million | Press release | GlobeNewswire | +0.21% | -0.36% | |
| Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement | Press release | GlobeNewswire | +0.13% | -0.89% | |
| Royalty Pharma to Present at Upcoming Investor Conferences | Press release | GlobeNewswire | -0.53% | +0.30% | |
| Form 10-Q Royalty Pharma plc For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +4.63% | +10.44% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the RPRX section they belong to.
Where else RPRX is measured.
RPRX earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Royalty Pharma plc - Class A Ordinary Shares's median reaction calculated?
Every labeled RPRX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 382 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 55% of RPRX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does RPRX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.